[go: up one dir, main page]

WO1996022067A3 - Banques de peptides a encliquetage pour vaccins et therapeutiques induisant des lymphocytes t cytotoxiques - Google Patents

Banques de peptides a encliquetage pour vaccins et therapeutiques induisant des lymphocytes t cytotoxiques Download PDF

Info

Publication number
WO1996022067A3
WO1996022067A3 PCT/US1995/016290 US9516290W WO9622067A3 WO 1996022067 A3 WO1996022067 A3 WO 1996022067A3 US 9516290 W US9516290 W US 9516290W WO 9622067 A3 WO9622067 A3 WO 9622067A3
Authority
WO
WIPO (PCT)
Prior art keywords
ratchet
ctl
libraries
peptide
therapeutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/016290
Other languages
English (en)
Other versions
WO1996022067A2 (fr
Inventor
Peter J Kuebler
Douglas F Nixon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Biomedical Inc
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Priority to AU58497/96A priority Critical patent/AU5849796A/en
Publication of WO1996022067A2 publication Critical patent/WO1996022067A2/fr
Publication of WO1996022067A3 publication Critical patent/WO1996022067A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des banques à encliquetage constituées de peptides voisins synthétisés simultanément lors d'une synthèse unique de peptides. Les banques à encliquetage sont dérivées d'un peptide à matrice plus longue en 'encliquetant' séquentiellement la séquence de matrice dans la plus faible longueur d'encliquetage, et elles sont utilisées pour induire ou stimuler des lymphocytes T cytotoxiques (LTC), si l'épitope des LTC est connu. Si l'épitope des LTC est inconnu, on peut utiliser la banque à encliquetage pour identifier des épitopes de LTC. Les banques à encliquetage peuvent être préparées à partir de toute séquence protéique pour laquelle on désire une réaction LTC immunitaire, et on peut leur donner une formule pour l'administration en tant que vaccin ou que thérapeutique, dans le traitement ou la prévention d'une maladie ou d'une affection maligne. Par exemple, une banque à encliquetage peut être utilisée dans la prévention et le traitement de maladies infectieuses ou malignes, y compris le VIH, la grippe, le paludisme et les cancers du sein, des ovaires, du poumon et du côlon.
PCT/US1995/016290 1994-12-27 1995-12-15 Banques de peptides a encliquetage pour vaccins et therapeutiques induisant des lymphocytes t cytotoxiques Ceased WO1996022067A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58497/96A AU5849796A (en) 1994-12-27 1995-12-15 Peptide ratchet libraries for ctl-inducing vaccines and therapeutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36633294A 1994-12-27 1994-12-27
US08/366,332 1994-12-27

Publications (2)

Publication Number Publication Date
WO1996022067A2 WO1996022067A2 (fr) 1996-07-25
WO1996022067A3 true WO1996022067A3 (fr) 1996-11-28

Family

ID=23442575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016290 Ceased WO1996022067A2 (fr) 1994-12-27 1995-12-15 Banques de peptides a encliquetage pour vaccins et therapeutiques induisant des lymphocytes t cytotoxiques

Country Status (2)

Country Link
AU (1) AU5849796A (fr)
WO (1) WO1996022067A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
WO1997011958A1 (fr) * 1995-09-29 1997-04-03 The Scripps Research Institute Analyse de signature de proteine
DE69723434T2 (de) * 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
DK1634949T3 (da) * 1997-05-08 2011-03-28 Oncothyreon Inc Fremgangsmåde til at generere aktiverede T-celler og antigen-inkuberede antigen-præsenterende celler
WO1999023114A1 (fr) * 1997-10-31 1999-05-14 Biomira Inc. Derives de muc-1 et leur utilisation pour traiter l'immuno-depresseur induite par mucine muc-1 et associee au cancer
EP1369428A1 (fr) * 1997-10-31 2003-12-10 Biomira Inc. Dérivés de Muc-1 et leur utilisation dans le traitement d'immunosupression induite par le MUC-1 Mucin associé au cancer
NZ506839A (en) * 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
GB9904695D0 (en) * 1999-03-01 1999-04-21 Imp Cancer Res Tech Peptide
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
WO2001036452A2 (fr) 1999-11-18 2001-05-25 Epimmune Inc. Analogues heteroclites et procedes associes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
RU2172322C1 (ru) * 1999-12-27 2001-08-20 Энтофарм Ко., Лтд. Аллофероны-иммуномодулирующие пептиды
FR2809402A1 (fr) * 2000-05-26 2001-11-30 Dev Des Antigenes Combinatoire Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
US10238747B2 (en) * 2010-12-13 2019-03-26 Cel-Sci, Corp Method for inducing an immune response against avian, swine, spanish, H1N1, H5N9 influenza viruses and formulations thereof
US10179174B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corp. Method for inducing an immune response and formulations thereof
WO2023023523A1 (fr) * 2021-08-16 2023-02-23 Duke University Vaccins de nouvelle génération comprenant des banques antigéniques et leurs procédés de préparation et leurs méthodes d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000091A1 (fr) * 1990-07-02 1992-01-09 Bioligand, Inc. Banque de bio-oligomeres aleatoires, son procede de synthese et son mode d'emploi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000091A1 (fr) * 1990-07-02 1992-01-09 Bioligand, Inc. Banque de bio-oligomeres aleatoires, son procede de synthese et son mode d'emploi

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
E.BORGES E.A.: "efficacy of synthetic vaccines in the induction of cytotoxic t lymphocytes", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 173, no. 2, 1 August 1994 (1994-08-01), NEW YORK US, pages 253 - 263, XP002014811 *
J.A.SMITH E.A.: "PEPTIDES,chemistry and Biology; Proc.12th Am. Pept. Symp.", 1992, ESCOM, LEIDEN, XP002014814 *
J.ESTAQUIER E.A.: "The mixotope: a combinatorial peptide library as a T cell and B cell immunogen", EUR.J.IMMUNOL., vol. 24, November 1994 (1994-11-01), pages 2789 - 2795, XP002014810 *
J.RUPPERT E.A: "Class I MHC-peptide interaction: structural and functional aspects", BEHRING INSTITUTE MITTEILUNGEN, no. 94, July 1994 (1994-07-01), pages 48 - 60, XP002014809 *
K DERES E.A.: "In vivo priming of virus specific CTL's with synthetic peptides", NATURE, vol. 342, 30 November 1989 (1989-11-30), pages 561 - 564, XP002014812 *
M.FRIEDE E.A.: "Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomesŸ", VACCINE, vol. 12, no. 9, 1994, pages 791 - 797, XP002014813 *
R.H.MELOEN E.A.: "The use of peptides to reconstruct conformational determinants", ANNALES DE BIOLOGIE CLINIQUE, vol. 49, no. 4, April 1991 (1991-04-01), pages 231 - 242, XP002014808 *

Also Published As

Publication number Publication date
WO1996022067A2 (fr) 1996-07-25
AU5849796A (en) 1996-08-07

Similar Documents

Publication Publication Date Title
WO1996022067A3 (fr) Banques de peptides a encliquetage pour vaccins et therapeutiques induisant des lymphocytes t cytotoxiques
CA2077537C (fr) Peptides et fragments peptidiques a action therapeutique
CA2143823A1 (fr) Analogues synthetiques de peptides, modifies pour la reversion, l'inversion et la reversion-inversion
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
EP0752876A4 (fr) Anticorps monoclonaux qui se fixent a un precurseur de l'antigene de rejet de tumeurs et qui est du type mage-1, mage-1 produit par recombinaison ou un peptide immunogene derive de mage-1
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
CA2204666A1 (fr) Immunotherapie specifique contre le cancer a l'aide d'un vecteur de vaccin bacterien de recombinaison vivant
MA24638A1 (fr) Vaccin
NO955063D0 (no) Isolerte peptider som danner komplekser av MHC-molekylet HLA-C-klon 10, samt anvendelse derav
Hans et al. Current status of short synthetic peptides as vaccines
WO2000073430A3 (fr) Vaccins contre des antigenes dependant de la conformation ainsi que contre des antigenes qui ne sont pas ou pas exclusivement des proteines ou des peptides
WO1989002277A3 (fr) Prophylaxie et therapie du syndrome immunodeficitaire acquis
WO2002032923A3 (fr) Formulations ameliorees utilisant des complexes peptides-proteines de choc thermique/de stress
ZA936970B (en) Anti-feline immunodeficiency virus (FIV) vaccines
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
DE60313437D1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
CA2440610A1 (fr) Induction de l'immunite tumorale par des variantes de la proteine de fixation a folate
GR3024670T3 (en) Induction of protection against viral infection
MXPA04000652A (es) Identificacion de antigenos especificos del tumor por medio de seleccion de bibliotecas de acido desoxirribonucleico complementario con sueros y uso de antigenos en tratamiento de tumores.
Shanmugam et al. Identification of peptide mimotopes of gp96 using single-chain antibody library
AU2001252262B2 (en) Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
SE9902989D0 (sv) Novel compounds
EP0320034A3 (fr) Peptides synthétiques immunologiquement actifs utilisables pour préparer un vaccin contre le paludisme
AU2024225671A1 (en) Vaccines against tert-positive tumors
Loibner et al. Vaccination of rhesus monkeys with an anti-idiotype antibody mumicking Lewis Y: Enhancement of the anti-tumor immune response by repeated administrations of recombinant human GM-CSF.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA